Home › Compare › EVLI vs MRK

EVLI vs MRK: Dividend Comparison 2026

EVLI yields 17094.02% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVLI wins by $11055119148194668544.00M in total portfolio value
10 years
EVLI
EVLI
● Live price
17094.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11055119148194668544.00M
Annual income
$10,929,346,032,583,308,000,000,000.00
Full EVLI calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — EVLI vs MRK

📍 EVLI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVLIMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVLI + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EVLI pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVLI
Annual income on $10K today (after 15% tax)
$1,452,991.45/yr
After 10yr DRIP, annual income (after tax)
$9,289,944,127,695,812,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, EVLI beats the other by $9,289,944,127,695,812,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVLI + MRK for your $10,000?

EVLI: 50%MRK: 50%
100% MRK50/50100% EVLI
Portfolio after 10yr
$5527559574097334272.00M
Annual income
$5,464,673,016,291,654,000,000,000.00/yr
Blended yield
98.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EVLI
No analyst data
Altman Z
-59.0
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVLI buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVLIMRK
Forward yield17094.02% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$11055119148194668544.00M ✓$30.7K
Annual income after 10y$10,929,346,032,583,308,000,000,000.00 ✓$950.29
Total dividends collected$11046808408481701888.00M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EVLI vs MRK ($10,000, DRIP)

YearEVLI PortfolioEVLI Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,720,102$1,709,401.71$11,192$351.54+$1.71M → EVLI
2$276,639,088$274,798,579.66$12,524$392.70+$276.63M → EVLI
3$41,599,814,704$41,303,810,879.20$14,015$438.65+$41599.80M → EVLI
4$5,849,270,848,201$5,804,759,046,467.79$15,682$489.96+$5849270.83M → EVLI
5$769,058,843,578,800$762,800,123,771,225.10$17,547$547.23+$769058843.56M → EVLI
6$94,554,230,856,881,740$93,731,337,894,252,450.00$19,632$611.16+$94554230856.86M → EVLI
7$10,871,339,943,330,447,000$10,770,166,916,313,584,000.00$21,963$682.53+$10871339943330.43M → EVLI
8$1,168,918,512,140,847,200,000$1,157,286,178,401,483,600,000.00$24,571$762.18+$1168918512140847.25M → EVLI
9$117,544,967,861,083,200,000,000$116,294,225,053,092,500,000,000.00$27,486$851.08+$117544967861083200.00M → EVLI
10$11,055,119,148,194,668,000,000,000$10,929,346,032,583,308,000,000,000.00$30,745$950.29+$11055119148194668544.00M → EVLI

EVLI vs MRK: Complete Analysis 2026

EVLI — Stock

Everlert, Inc. provides strategic management and structured financing services focusing on entertainment and real estate business sectors in Southern California. It offers entertainment related services and projects in the areas of management, new entertainment content development and acquisition, and structural financing solutions to entertainment projects. The company also develops and operates senior assisted living facilities in the Inland Empire region of Southern California. In addition, it provides consumer financial services, such as payday loans, car title loans, bail bonds, and pawnshop services. The company was incorporated in 1998 and is based in Los Angeles, California.

Full EVLI Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this EVLI vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVLI vs SCHDEVLI vs JEPIEVLI vs OEVLI vs KOEVLI vs MAINEVLI vs JNJEVLI vs ABBVEVLI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.